Abstract:Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y 12 receptor inhibitor is the standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several trials have challenged guideline-recommended DAPT after PCI by testing the relative clinical effect of an aspirin-free antiplatelet approach—consisting of P2Y 12 inhibitor monotherapy after a short course (mostly 1–3 months) of DAPT—among patients undergoing PCI without a concomitant indication for oral anticoagulation (OAC). Overall, these studies have shown P2Y 12 inhibitor monotherapy after short DAPT to be associated with a significant reduction in the risk of bleeding without an increase in thrombotic or ischaemic events compared with continued DAPT. Moreover, the effects of the P2Y 12 inhibitor monotherapy without prior DAPT or following a very short course of DAPT after PCI are being investigated in emerging studies, of which one has recently reported unfavourable efficacy results associated with the aspirin-free approach compared with conventional DAPT. Finally, P2Y 12 inhibitor alone has been compared with aspirin alone as chronic therapy after DAPT discontinuation, thus challenging the historical role of aspirin as a standard of care for secondary prevention following PCI. A thorough understanding of study designs, populations, treatments, results, and limitations of trials testing P2Y 12 inhibitor monotherapy vs. DAPT or vs. aspirin is required to consider adopting this treatment in clinical practice. This review addresses the use of aspirin-free antiplatelet strategies among patients undergoing PCI without a concomitant indication for OAC, providing an overview of clinical evidence, guideline indications, practical implications, ongoing issues, and future perspectives. Studies on aspirin-free antiplatelet approaches after percutaneous coronary intervention (PCI) can be divided into two groups: (i) those comparing P2Y 12 inhibitor monotherapy vs. dual antiplatelet therapy (DAPT) after PCI in patients with and without concomitant indication for oral anticoagulation (OAC) and (ii) those comparing P2Y 12 inhibitor monotherapy vs. aspirin monotherapy after DAPT discontinuation or in patients with established coronary artery disease (CAD), including prior PCI patients. Among studies of the first group, one recent study assessing an aspirin-free treatment since the PCI time has shown that monotherapy with low-dose prasugrel vs. DAPT was associated with increased 30-day thrombotic events; other studies assessing the P2Y 12 inhibitor monotherapy after very short DAPT limited to the peri-PCI time are ongoing. The other studies of the first group have shown that P2Y 12 inhibitor monotherapy following a short course of DAPT after PCI (<1 month in one study and 1–3 months in most studies) or combined with OAC was associated with decreased bleeding and similar overall ischaemic events compared with conventional DAPT. Overall studies of the second group have shown that P2Y 12 inhibitor monotherapy (clopidogrel or ticagrelor) vs. aspirin was associated with similar bleeding, reduced myocardial infarction (MI) with a number needed to treat (NNT) > 100 across studies, and comparable mortality. ST, stent thrombosis.

Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications

Dual Antiplatelet Therapy for the Acute Management and Long-term Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack, An Updated Review

Dual antiplatelet therapy for ischemic stroke with intracranial arterial stenosis: a systematic review and meta-analysis

P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack.

Dual vs. mono antiplatelet therapy for acute ischemic stroke or transient ischemic attack with evidence of large artery atherosclerosis

Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines

The use of dual antiplatelet therapy for ischemic cerebrovascular events

Efficacy and safety of P2Y12 inhibitors plus aspirin versus aspirin alone in ischemic stroke or high-risk transient ischemic attack: a meta-analysis of randomized controlled trials

Baseline Stroke Risk and Efficacy of Dual-Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial

Indications for Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Evidence-Based Recommendations for Use

Dual antiplatelet therapy after intravenous thrombolysis for patients with minor ischemic stroke：A meta-analysis

Efficacy and safety of aspirin plus clopidogrel versus aspirin alone in ischemic stroke or high-risk transient ischemic attack: A meta-analysis of randomized controlled trials

Effect of Dual- Versus Single-Antiplatelet Therapy on Early Neurological Deterioration in Minor Stroke of Undetermined Cause

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how

Strategy of dual antiplatelet therapy for patients with ST-elevation myocardial infarction and non-ST-elevation acute coronary syndromes: A systematic review and network meta-analysis

Abstract TMP64: Time-Trends and Determinants of Dual Antiplatelet Therapy Prescription After Acute Moderate-to-Severe Non-Cardioembolic Ischemic Stroke

Efficacy and Safety of Long-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis

Treatment strategies and prognosis for moderate stroke patients in China

Trends in Dual Antiplatelet Therapy of Aspirin and Clopidogrel and Outcomes in Ischemic Stroke Patients Noneligible for POINT/CHANCE Trial Treatment

Advances in Early Anti-Platelet Therapy in Patients with Ischemic Stroke and Transient Ischemic Attack

Aspirin-free antiplatelet strategies after percutaneous coronary interventions